395100-12-6

Basic information

• Product Name: 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile
• Synonyms: 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile
• CAS NO: 395100-12-6
• Molecular Formula: C₁₄H₈FN₃
• Molecular Weight: 237.2318232
• Mol File: 395100-12-6.mol

Chemical Properties

• Appearance: /
• Density: 1.38
• CAS DataBase Reference: 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile(395100-12-6)
• EPA Substance Registry System: 3-(4-Fluorophenyl)-1H-indazole-5-carbonitrile(395100-12-6)

Safety Data

• Hazardous Substances Data: 395100-12-6(Hazardous Substances Data)

Upstream product

• 473416-06-7 tert-butyl 3-bromo-5-cyano-1H-1-indazolecarboxylate 
• 1765-93-1 4-fluoroboronic acid 
• 395100-11-5 4-fluoro-3-(4-fluorobenzoyl)benzonitrile 

Downstream Products

• 716320-97-7 3-(4-fluorophenyl)-1H-indazole-5-carboximidic acid ethyl ester hydrochloride 
• 395100-10-4 3-(4-fluorophenyl)-1H-indazole-5-carboxylic acid 

Relevant articles and documents

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

Methods for treating an inflammatory condition or inhibiting JNK

This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

NOVEL 1H-INDAZOLE COMPOUND

The present invention provides a novel 1H-indazole compound having an excellent JNK inhibitory action. More specifically, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 is a C6-C14 aromatic cyclic hydrocarbon group etc.; R2, R4 and R5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C1-C6 alkylene group etc.; X is a single bond, or a group represented by -CO-NH- or -NH-CO-, etc.; and Y is a C3-C8 cycloalkyl group, a C6-C14 aromatic cyclic hydrocarbon group or a 5- to 14-membered aromatic heterocyclic group etc.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.